Please note: This trial has finished recruiting and is not accepting new participants.

Research Center: Avita Clinical Research
Location: 14829 N Florida Ave, Tampa, FL 33613
Lead Doctor: Thomas Taylor, MD
IRB Committee: This study has been reviewed and approved by Copernicus Group Institutional Review Board

Background

Vitiligo is a skin condition characterized by smooth, white patches on the skin. It can occur in areas on both sides of the body but can also affect just one small area of the skin. The cause is unclear, although it is believed to be an autoimmune condition that results in the destruction of skin pigment cells. 

Currently, there are limited treatment options available to treat the condition. Therefore, a study in Florida is exploring an investigational topical medication that may prevent the loss of skin pigmentation in people with vitiligo.

This study seeks male and female diagnosed with non-segmental vitiligo. Participants are required to discontinue their current treatment and only use the investigational topical medication and those treatments approved for use in the study.

Why Participate? 

• You may see an improvement in the pigmentation of your skin.
• You will be reimbursed up to $1300 ($100 per study visit) for participating in this study
• You will be helping to advance medical research relating to vitiligo.

Your Rights

• If you decide to participate in the study and later feel that you no longer wish to be part of it, you may withdraw at any time.
• Your records relating to this study and any other information received will be kept strictly confidential, except as required by law.
• Qualified health professionals will monitor your health as it relates to the study.

Who Can Participate?

• Men and women aged 12 and older who are diagnosed with non-segmental  vitiligo.
• Willing to discontinue current vitiligo treatment.
• Has no other skin conditions apart from vitiligo.
• Able to attend 13 study visits at the research site over approximately 1 year.